StockData
Inmune Bio, Inc. logo

Inmune Bio, Inc. (INMB) stock

INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.95−0.10 (-9.87%)

Close on Nov 16, 2026Market cap $26.27MP/E –Yield –

Inmune Bio profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Inmune Bio's profit margin for the twelve months ending Dec 31, 2025 was -91866.0%. For fiscal 2025 it was -91866.0%, against -300585.7% the year before. The highest annual figure on record is -7299.2% in fiscal 2022.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-91866.0%+208719.7
FY2024Dec 31, 2024-300585.7%−281225.7
FY2023Dec 31, 2023-19360.0%−12060.8
FY2022Dec 31, 2022-7299.2%+9463.2
FY2021Dec 31, 2021-16762.4%+93228.5
FY2020Dec 31, 2020-109990.9%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2025Mar 31, 2025-19478.0%−5345.4
Q1 FY2024Mar 31, 2024-78750.0%−61550.0
Q4 FY2023Dec 31, 2023-30028.6%−24015.2
Q3 FY2023Sep 30, 2023-19914.0%−12031.3
Q2 FY2023Jun 30, 2023-14132.6%+28604.9
Q1 FY2023Mar 31, 2023-17200.0%−12965.0
Q4 FY2022Dec 31, 2022-6013.4%−80.3
Q3 FY2022Sep 30, 2022-7882.7%+59674.5
Q2 FY2022Jun 30, 2022-42737.5%+71162.5
Q1 FY2022Mar 31, 2022-4235.0%–
Q4 FY2021Dec 31, 2021-5933.1%–
Q3 FY2021Sep 30, 2021-67557.1%–
Q1 FY2021Mar 31, 2021-113900.0%–

More Inmune Bio figures

See a number that looks wrong?